Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.
about
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesHemophagocytic syndromes and infectionOptimal treatment for chronic active Epstein-Barr virus diseaseHemophagocytic lymphohistiocytosis: review of etiologies and managementHemophagocytic syndrome in children and adultsA case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder.Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis.Clinical presentation of hemophagocytic lymphohistiocytosis in adults is less typical than in childrenSuccessful treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-94 protocolNovel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells.Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series.Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferationsHow I treat hemophagocytic lymphohistiocytosis.Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocolVirus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection.Massive expansion of EBV+ monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis.Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2.The role of plasmapheresis in critical illness.Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailableEpstein-barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting.Epstein-barr virus-induced hemophagocytic lymphohistiocytosis.Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.
P2860
Q24617384-ABC3FCFF-6343-4445-9EB6-CF8256AC61BCQ24653852-FE062A07-F89B-4EC2-9670-13E46A556F3CQ24657703-5493AEEA-97A0-42A8-9BE6-5789B913CAF7Q26830538-C645E3C2-0215-425A-B827-69274BFE36BDQ27004580-8FBF92D0-E51E-459F-A7DE-EF8C7A765450Q33362585-6D320048-CBC0-4292-87D2-1B83E251A6D9Q33380111-FD9889C3-4989-465C-848C-57A0B896926EQ33432151-42AC74E2-B83C-45D3-AE56-FB4A84A9E365Q33599483-251E47C8-1FBB-4093-9F2D-963170BF9634Q34058148-42100D50-A2A3-43B2-BD4A-CB07906188F5Q34412662-04625CD1-9E15-4358-94D4-90E4E9D69D79Q35232848-5A2ED91E-1FE1-4556-A29D-546B889CD539Q35483540-84BFC42C-C971-4AE9-BBF3-D3589A3E949CQ35525318-44497608-2C37-446C-951D-CDFCDE9AE897Q35559362-CF7057EC-033D-40AE-9952-6104C3F377B3Q35770684-CA39A71E-FF5C-4BDA-A5D8-B4F80547E56EQ35819248-500B514A-B775-44AD-9691-77769908B826Q36053839-2216799F-20FB-4BBB-870D-3E889BEDABE2Q36253959-A9B26168-8115-477D-BD43-83EB7F174A90Q36686045-269778C0-50D8-4C91-9254-8C6DA6EEA14BQ38371707-C81D7716-4CEF-4A32-886F-EB8E5F50A03EQ41911594-38DB5DF7-18E4-47BC-8231-2FC05DBC9709Q42260141-8E18B821-C044-46A2-A51D-4DE14D437B48Q47945740-401238E8-DC5F-4C82-9597-56C0A499ACCF
P2860
Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@en
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@nl
type
label
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@en
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@nl
prefLabel
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@en
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@nl
P2093
P1433
P1476
Effective control of Epstein-B ...... motherapy. Histiocyte Society.
@en
P2093
Hasegawa D
Hisakawa H
Igarashi N
P304
P407
P577
1999-03-01T00:00:00Z